Saturday, October 31, 2026

Xerox Corporation Stock Bullish By 13% So Far Today

Xerox Corporation Stock Bullish By 13% So Far Today

(VIANEWS) - Shares of Xerox Corporation (NYSE: XRX) jumped by a staggering 13.65% to $15.44 at 11:50 EST on Tuesday, after five sequential sessions in a row of losses. NYSE is dropping 0.87% to $15,471.41, following the last session's upward trend. This seems, so far, a somewhat bearish trend exchanging session today.

Xerox Corporation's last close was $13.59, 33.02% under its 52-week high of $20.29.

About Xerox Corporation

Xerox Holdings Corporation, a workplace technology company, designs, develops, and sells document management systems and solutions in the Americas, Europe, the Middle East, Africa, India, and internationally. It offers workplace solutions, including desktop monochrome, and color and multifunction printers; digital printing presses and light production devices, and solutions; and digital services that leverage workflow automation, personalization and communication software, content management solutions, and digitization services. The company also provides graphic communications and production solutions; and IT services, end user computing devices, network infrastructure, communications technology, and a range of managed IT solutions, such as technology product support, professional engineering, and commercial robotic process automation; and provides finance for the sale of Xerox, non-Xerox office, and IT services equipment. In addition, it provides FreeFlow a portfolio of software solutions for the automation and integration to the processing of print job comprises file preparation, final production, and electronic publishing. Further, the company sells paper products and wide-format systems, licensing, as well as standalone software such as CareAR, DocuShare, and XMPie. The company sells its products and services directly to its customers through its direct sales force, as well as through independent agents, dealers, value-added resellers, systems integrators, and e-commerce marketplaces. Xerox Holdings Corporation was founded in 1906 and is headquartered in Norwalk, Connecticut.

Earnings Per Share

As for profitability, Xerox Corporation has a trailing twelve months EPS of $-2.15.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -7.81%.

Yearly Top and Bottom Value

Xerox Corporation's stock is valued at $15.44 at 11:50 EST, way below its 52-week high of $20.29 and way higher than its 52-week low of $11.80.

Revenue Growth

Year-on-year quarterly revenue growth grew by 9.2%, now sitting on 7.11B for the twelve trailing months.

Moving Average

Xerox Corporation's worth is under its 50-day moving average of $15.73 and below its 200-day moving average of $15.75.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Xerox Corporation's EBITDA is 22.21.

More news about Xerox Corporation (XRX).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com